Two years after ending its own internal neuroscience research and early development programs, Thousand Oaks-based Amgen has found a way to get the sector back into its portfolio. Neumora Therapeutics, a Massachusetts-based developer of drugs for brain diseases, officially launched on Oct. 7, with a strategic partnership between the two companies that includes global rights…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
